Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Baseline characteristics of patients

From: Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis

Characteristics

Patients, no. (%) (N = 31)

Age, years

Median (range)

58 (32–72)

Sex

 Female

22 (71.0)

 Male

9 (29.0)

Smoking status

 Former

7 (22.6)

 Never

24 (77.4)

ECOG-PS

 0

18 (58.1)

 1

13 (41.9)

EGFR mutation type

 Ex19 del

18 (58.1)

 L858R

13 (41.9)

Prior EGFR-TKI

 Gefitinib

15 (48.4)

 Erlotinib

4 (12.9)

 Icotinib

11 (35.5)

 Dacomitinib

1 (3.2)

Brain metastasis

 No

24 (77.4)

 Yes

7 (22.6)

Liver metastasis

 No

28 (90.3)

 Yes

3 (9.7)

Bone metastasis

 No

19 (61.3)

 Yes

12 (38.7)

Pleural metastasis

 No

24 (77.4)

 Yes

7 (22.6)

Adrenal gland metastasis

 No

29 (93.5)

 Yes

2 (6.5)

  1. ECOG-PS, the Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor gene; Ex19 del, exon 19 deletion
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us